middle.news
Actinogen Reaches 100 Participants in Pivotal Alzheimer’s Trial, Eyes 2026 Data Milestone
9:06am on Monday 30th of June, 2025 AEST
•
Healthcare
Read Story
Actinogen Reaches 100 Participants in Pivotal Alzheimer’s Trial, Eyes 2026 Data Milestone
9:06am on Monday 30th of June, 2025 AEST
Key Points
100+ participants enrolled in XanaMIA Alzheimer’s trial
Interim safety and efficacy futility analysis scheduled for January 2026
Final trial results expected in Q4 2026 with 220 participants
FDA meeting planned in H2 2025 to discuss regulatory pathways
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACW
OPEN ARTICLE